Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Sells $185,478.00 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Karah Herdman Parschauer sold 8,135 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $185,478.00. Following the completion of the transaction, the executive vice president directly owned 76,346 shares in the company, valued at $1,740,688.80. This trade represents a 9.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ultragenyx Pharmaceutical Trading Down 4.1%

Ultragenyx Pharmaceutical stock traded down $0.95 during mid-day trading on Tuesday, hitting $22.07. 1,722,117 shares of the company’s stock were exchanged, compared to its average volume of 2,060,535. The stock has a 50 day moving average of $23.82 and a two-hundred day moving average of $29.24. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.41 and a 1-year high of $42.37. The stock has a market cap of $2.13 billion, a P/E ratio of -3.78 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The firm had revenue of $207.28 million for the quarter, compared to analyst estimates of $199.60 million. During the same period in the prior year, the firm earned ($1.39) EPS. The firm’s revenue was up 25.5% on a year-over-year basis. As a group, research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on RARE. Wedbush reiterated a “neutral” rating and issued a $25.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, February 17th. Bank of America cut their price target on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, January 2nd. Guggenheim lowered their price target on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research report on Monday, January 5th. Robert W. Baird dropped their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. Finally, Jefferies Financial Group dropped their price objective on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a research report on Tuesday, December 30th. Sixteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $68.29.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of RARE. Caitong International Asset Management Co. Ltd increased its stake in shares of Ultragenyx Pharmaceutical by 1,116,754.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 122,854 shares of the biopharmaceutical company’s stock worth $2,826,000 after purchasing an additional 122,843 shares in the last quarter. Alberta Investment Management Corp purchased a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at about $883,000. Mercer Global Advisors Inc. ADV raised its position in shares of Ultragenyx Pharmaceutical by 17.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,965 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 2,036 shares in the last quarter. Krensavage Asset Management LLC bought a new stake in Ultragenyx Pharmaceutical during the fourth quarter worth about $3,442,000. Finally, Empowered Funds LLC purchased a new stake in Ultragenyx Pharmaceutical in the fourth quarter worth approximately $66,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Management presentation transcript from TD Cowen’s 46th Annual Health Care Conference is available; this is informational for modeling product timelines and pipeline commentary but contains no new regulatory decisions. TD Cowen Presentation Transcript
• Negative Sentiment: Large, concentrated insider selling by multiple senior executives (CEO Emil Kakkis sold 54,404 shares; several EVPs, the CFO and CAO also sold material blocks) — these trades reduced several insiders’ holdings by ~3–10% and totaled well over $1M for the CEO alone. Such coordinated/large insider liquidity can signal personal cash needs or tax planning, but markets often read it as a negative signal for near-term sentiment. SEC filing (CEO sale) here: Insider Sale SEC Filing
• Negative Sentiment: Multiple law firms have announced or are soliciting lead plaintiffs for a securities-fraud class action (alleging misstatements/omissions related to setrusumab) covering Aug 3, 2023–Dec 26, 2025; several firms set April 6 lead‑plaintiff deadlines. The proliferation of notices and a filed class action increases legal and financial uncertainty and is likely exerting downward pressure on the stock. Example notice: Kessler Topaz Class Action Notice

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.